A Review of Autologous Stem Cell Transplantation in Lymphoma
- 1.2k Downloads
Purpose of Review
Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients.
There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL.
Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.
KeywordsHigh-dose chemotherapy Autologous stem cell transplantation Relapsed/refractory Lymphoma Salvage chemotherapy Novel agents
This work was supported by grant P30 CA023074 from the National Cancer Institute, National Institutes of Health, Bethesda, MD.
UZ, FA, AA, MH, OC, IBR, AM, AI, and FAα designed the study. All coauthors searched for studies, extracted data, summarized results, developed the manuscript, helped with final edits, and wrote the paper. Ali McBride PharmD MS and Faiz Anwer MD FACP will share senior authorship for this manuscript, and FAα will serve as corresponding author.
Compliance With Ethical Standards
Conflict of Interest
Umar Zahid, Faisal Akbar, Akshay Amaraneni, Muhammad Husnain, Onyee Chan, Irbaz Bin Riaz, Ali McBride, and Ahmad Iftikhar each declare no potential conflicts of interest.
Faiz Anwer reports grants from the National Cancer Institute and National Institutes of Health.
Human and Animal Rights
This article does not contain any data involving human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71.CrossRefPubMedGoogle Scholar
- 6.Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, et al. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). BMC Cancer. 2016;16:282.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Arakelyan N, Berthou C, Desablens B, de Guibert S, Delwail V, Moles MP, et al. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Cancer. 2008;113(12):3323–30.CrossRefPubMedGoogle Scholar
- 8.Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J Clin Oncol. 2003;21(12):2320–5.CrossRefPubMedGoogle Scholar
- 9.Morschhauser F, Brice P, Ferme C, Divine M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008;26(36):5980–7.CrossRefPubMedGoogle Scholar
- 11.Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21(5):855–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Columbia University. Autologous and allogeneic transplant for relapsed lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[January 14.
- 13.Yun S, Vincelette ND, Abraham I, Puvvada S, Anwer F. Outcome comparison of allogeneic versus autologous stem cell transplantation in transformed low-grade lymphoid malignancies: a systematic review and pooled analysis of comparative studies. Acta Haematol. 2016;136(4):244–55.CrossRefPubMedGoogle Scholar
- 14.Fred Hutchinson Cancer Research Center. Autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treatment patients with high-risk Hodgkin lymphoma N-HL, multiple myeloma, or chronic lymphocytic leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[January 14, 2017]. Available from:.
- 16.Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016.Google Scholar
- 18.Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758–65.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. . ASH 58th Annual Meeting & Exposition; December 3–6, 2016; San Diego, CA, 2016.Google Scholar
- 22.Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia. 2007;21(8):1802–11.CrossRefPubMedGoogle Scholar
- 23.Vitolo U, Chiappella A, Angelucci E, Rossi G, Liberati AM, Cabras MG, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica. 2009;94(9):1250–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Kim YR, Kim SJ, Cheong JW, Yang DH, Lee H, Eom HS, et al. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. Ann Hematol. 2016;95(9):1491–501.CrossRefPubMedGoogle Scholar
- 25.Kaneko H, Tsutsumi Y, Fujino T, Kuwahara S, Ohshiro M, Iwai T, et al. Favorable event free-survival of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for higher risk diffuse large B-cell lymphoma in first complete remission. Hematol Rep. 2015;7(2):5812.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.• Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–6. This randomized study including over 600 patients showed the salvage chemotherapy regimen GDP before ASCT to be non-inferior and had less toxicities compared to the standard DHAP regimen for R/R DLBCL CrossRefPubMedGoogle Scholar
- 32.El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18(8):1363–8.CrossRefPubMedGoogle Scholar
- 33.Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079–87.CrossRefPubMedGoogle Scholar
- 35.• Chen YB, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–53. Large study including almost 5000 patients from the CIBMTR database found patients undergoing HDT with ASCT who received high-dose CBV conditioning regimen had worse outcomes compared to other regimens CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31(13):1662–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Landsburg DJ, et al. Benefit of consolidative autologous stem cell transplantation in first complete remission for patients with double hit lymphoma appears dependent on induction regimen intensity. (2016): 3455–3455.Google Scholar
- 40.Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677–84.CrossRefPubMedGoogle Scholar
- 41.Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Trumper L, Hallek M, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood. 2009;114(22):362–3.Google Scholar
- 42.Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–75.CrossRefPubMedGoogle Scholar
- 43.Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158(3):355–62.CrossRefPubMedGoogle Scholar
- 46.Strauss DJGJ, Myers J, Merke DP, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8:1173–86.CrossRefGoogle Scholar
- 47.Carella AM, Bellei M, Brice P, Gisselbrecht C, Visani G, Colombat P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results. Haematologica. 2009;94(1):146–8.CrossRefPubMedGoogle Scholar
- 48.Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–23.CrossRefPubMedGoogle Scholar
- 54.Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;6:CD009411.Google Scholar
- 55.Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease. Bone Marrow Transplant. 1999;23(11):1131–8.CrossRefPubMedGoogle Scholar
- 56.Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, et al. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;41(7):613–9.CrossRefPubMedGoogle Scholar
- 57.Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, et al. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2010;16(8):1145–54.CrossRefPubMedPubMedCentralGoogle Scholar
- 59.Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marcais A, et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group. Haematologica. 2016;101(4):474–81.CrossRefPubMedPubMedCentralGoogle Scholar
- 60.Moskowitz AJ, Schoder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284–92.CrossRefPubMedGoogle Scholar
- 61.Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase II trial of Brentuximab Vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–40.CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62.CrossRefPubMedGoogle Scholar
- 63.Ansell SM. Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res. 2016.Google Scholar
- 65.Moskowitz Cea. PD-1 blockade with the monoclonal antibody pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a phase 1b study presented at the 56th meeting of the American Society for Hematology; December 2014; San Francisco, CA.Google Scholar
- 66.Armand P TJ, et al. Nivolumab in patients (Pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039). . Blood 2015; 126(23): 583 [Oral and Poster Abstracts])Google Scholar
- 67.Armand P SM, Ribrag V, et al. . PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment. Preliminary results presented at the 57th meeting of the American Society for Hematology; 2015; Orlando, FL.Google Scholar
- 68.Moskowitz CH, Zinzani PL, Fanale MA, Armand P, Johnson NA, Radford JA, et al. Pembrolizumab in relapsed/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 Keynote-087 Study. Blood. 2016;128(22).Google Scholar
- 69.Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—a phase 2 study. Preliminary results presented at the meeting of the American Society for Clinical Oncology; June 2016; Chicago, IL.Google Scholar
- 70.Chen RW ZP, Fanale MA et al. . Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. . 2016 ASCO Annual Meeting J Clin Oncol 34, (suppl; abstr 7555), 2016.Google Scholar
- 71.Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–94.CrossRefPubMedGoogle Scholar
- 72.Hatake K KT, Fukuhara N et al. . Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): an interim analysis. . 2016 ASCO Annual Meeting J Clin Oncol 34, 2016 (suppl; abstr e19018), 2016.Google Scholar
- 77.Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159–66.CrossRefPubMedGoogle Scholar
- 78.Delmer A, et al. . Intensified induction therapy with etoposide (VP16) and high-dose cytarabine (Ara-C) in patients aged less than 60 years with peripheral T cell/NK lymphoma: preliminary results of the phase II GELA study LNH98T7. . in Proc Am Soc Clin Oncol 2003.Google Scholar
- 79.Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25.CrossRefPubMedGoogle Scholar
- 82.• Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28(9):1885–91. A prospective trial studying the role of high dose chemo-immunotherapy with and without stem cell transplant in T cell Lymphoma CrossRefPubMedGoogle Scholar
- 84.Parovichnikova EN, Kuz’mina LA, Mendeleeva LP, Kliasova GA, Troitskaia VV, Sokolov AN, et al. Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: results of a Russian multicenter study. Ter Arkh. 2015;87(7):15–25.CrossRefPubMedGoogle Scholar
- 86.Malik SM, Liu K, Qiang X, Sridhara R, Tang S, McGuinn Jr WD, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2010;16(20):4921–7.CrossRefPubMedGoogle Scholar
- 87.A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas. Clin Adv Hematol Oncol. 2014;12(2 Suppl 6):3–4.Google Scholar
- 88.Makita S TK. Clinical features and current optimal management of natural killer/T-cell lymphoma. Hematology/Oncology Clinics of North America. 2017.Google Scholar
- 89.Yun S, Taverna JA, Puvvada SD, Anwer F. NK/T-cell non-Hodgkin’s lymphoma with secondary haemophagocytic lymphohistiocytosis treated with matched unrelated donor allogeneic stem cell transplant. BMJ Case Rep. 2014;2014.Google Scholar
- 91.Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;10(2):163–7.CrossRefPubMedGoogle Scholar
- 93.• Mounier N, Gill D, Linch D, Trneny M, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2016. Three independent factors (low to low-intermediate tIPI at relapse, progression > 6 months from ASCT, and chemosensitivities) predictive of improved outcomes were found using the famous CORAL cohort data for patients relapsed after autologous stem cell transplantation. Google Scholar